Latest Prostate Cancer News

Natural Treatment and Maintenance of Prostate Enlargement with New Thermobalancing Therapy Improves Men’s Well-being in Safety States Fine TreatmentFine Treatment recommends new Thermobalancing Therapy as successful natural solution for benign prostatic hyperplasia that is also the most cost-effective prostate treatment on the market. While long-term medication courses and BPH surgeries may cost thousands of dollars, the price of Dr. Allen’s Device for Prostate Treatment under $150 makes it widely affordable. London, UK (PRWEB) May 26, 2012...

Joy Keys Chats with the Faces of Stroke AmbassadorsPhiladelphia, PA, May 26, 2012 --(PR.com)-- Faces of Stroke Ambassadors Date: May 26th, 2012 Time: 11:00 a.m. – 11:30 a.m. ET Call In Number: 646-929-0368. Url: http://www.blogtalkradio.com/joykeys/2012/05/26/joy-keys-chats-with-the-faces-of-stroke-ambassadors Lenice Hogan: Hogan is a survivor of not one stroke, but three, all at young ages. She survived hemorrhagic strokes at the ages...

Saw palmetto no better than placebo in men with BPHNEW YORK (Reuters Health) - Saw palmetto, a fruit extract some men take to relieve the symptoms of an enlarged prostate, is no more effective than a sugar pill, according to the latest review of research on the herbal remedy.

Enzalutamide Is a 'Game Changer' in Prostate CancerAUA 2012: Enzalutamide, an androgen-receptor signaling inhibitor, improves survival in postdocetaxel prostate cancer, according to a phase 3 study. Medscape Medical News

Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate)NEW BRUNSWICK, N.J., May 25, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Ill. Results from pre-specified interim analyses of COU-AA-3...

New prostate cancer screening guidelines face a tough sell, study suggests(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback fro...

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meetingDiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the...

BPH Symptoms Can Be Improved with New Thermobalancing Therapy Without Potentially Harmful Drugs & Prostate Surgeries, Reveals Fine TreatmentThe improvement to BPH symptoms with the use of new Thermobalancing Therapy comes gradually; for instance, the urinary symptoms at first ease during the day and later in the night, Fine Treatment highlights. This therapy decreases the size of the enlarged prostate naturally without resorting to potentially harmful BPH drugs and prostate surgeries. London, UK (PRWEB) May 25, 2012 With the new Ther...

Towards an understanding of the genetic basis of prostate cancer

PCA3 Test Featured at American Urological Association MeetingDiagnoCure Management Responds to USPSTF Recommendation on Prostate Cancer Screening Ticker Symbol: CUR QUEBEC CITY, May 25, 2012 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and di...

Doctors disagree on new prostate cancer screening guidelinesOne doctor suggests the problem is the rush to treatment, not the screening; another suggests that a failure to screen men could be more costly in the long run.

Early baldness may be a risk factor for prostate cancerNEW YORK (Reuters Health) - Male pattern baldness may be an independent risk factor for prostate cancer, according to new research presented at the 107th Annual Scientific Meeting of the American Urological Association (AUA).

Why People Stick with Cancer Screening, Even When It Causes HarmThe data on PSA testing to detect prostate cancer has long been shaky -- so much so that the discoverer of PSA (or prostate-specific antigen, an enzyme made by the prostate) himself decried the test two years ago as "hardly more effective than a coin...

Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting- Presentations highlight first oral proteasome inhibitor in clinical trials in multiple myeloma patients -CAMBRIDGE, Mass., May 23, 2012 – with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that 101 abstracts featuring the Company’s oncology molecules have been accepted at the annual meeting of the American Socie...

Why I decided to get a PSA screening test for prostate cancerI’m a big believer in avoiding over-testing and over-treatment. So it might surprise you that I opted to undergo prostate-specific antigen (PSA) screening for prostate cancer right around the time that the US Preventive Services Task Force reco...

Psychological Aspects of Prostate CancerWhich issues most affect the psychological well-being of prostate cancer patients -- and what is the best way to support these patients and their caregivers? Prostate Cancer and Prostatic Diseases

Dendreon Falls as Analyst Starts CoverageNEW YORK (AP) — Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.

The Safeway Foundation and Stand Up To Cancer Raise Awareness and Funds in the Fight Against Prostate CancerActress Angie Harmon to Appear in Public Service Campaign about Prostate Cancer LOS ANGELES and PLEASANTON, Calif., May 24, 2012 /PRNewswire-USNewswire/ -- Actress and Stand Up To Cancer Ambassador Angie Harmon will appear in a new prostate cancer campaign on behalf of Stand Up To Cancer (SU2C) and The Safeway Foundation. The campaign is designed to raise funds and increase awareness for...

PSA test benefits are questionable, yet physicians struggle to stop themRecent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physi...

POM Wonderful Launches Advertising CampaignLOS ANGELES, May 24, 2012 /PRNewswire/ -- POM Wonderful, following the FTC Administrative Law Judge's ruling issued on Monday, May 21st, 2012, is exercising its right to legally advertise the general health benefits of its products, affirmed by the Judge, in an advertising campaign launching today. In POM's campaign, the Company will illuminate the facts and opinions stated in the ruling from the...

BPH Treatment Doesn't Have To Traumatize Sexual Function, But Possibly Improve It Like New Thermobalancing Therapy Does, States Fine TreatmentNew Thermobalancing Therapy has a positive impact on sexual function while treating the prostate and is free from adverse side effects, Fine Treatment highlights. This natural therapy favourably compares to a range of prostate treatments, surgeries and removals, such as TURP and TUMT, which may impair sexual function. London, UK (PRWEB) May 24, 2012 Unlike different conventional prostate removal...

UK's NICE Gives Thumbs Up to New Prostate Cancer Treatment Following Price DropLatest Decision from UK Health Authority Underscores Therapeutic Product Innovation Conundrum, according to RegLink News Washington, DC (PRWEB) May 24, 2012 The UK’s reimbursement watch dog, the National Institute for Clinical Excellence (NICE), has changed its mind and announced that it will after all propose the use by the National Health Service (NHS) of Janssen’s life extending new oral p...

CMS sticks with Medicare coverage of PSA testThe federal government is not changing coverage plans "at this time." Meanwhile, a number of urologists and other medical specialists raise concerns that new recommendations against prostate cancer screening will hurt men's health.

RARP more costly than RRP in treating prostate cancerIn one of the most comprehensive analyses to date of the cost of robotic-assisted, laparoscopic surgery for prostate cancer, researchers at UPMC found that this now-dominant surgical approach is significantly more costly than standard open surgery, d...

Viewpoints: The promise and perils of prostate screening; Presidential candidates shy away from frank discussion of spendingAfter an exhaustive process, the U.S. Preventive Services Task Force has announced its final recommendation on PSA-based prostate cancer screening. It finds that the known harms of screening outweigh the potential benefits for men who have no cancer...

0 1 2 3 4 ›»

buy Prostate Cancer market research data and corporate reports now Advertisement